Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

76.31 USD +0.82 (+1.09%)
Official Closing Price Updated: 7:59 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Merck & Co

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
80 81 Next >
Merck Resubmits Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule
Merck Resubmits Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule 
From Business Wire News Releases
Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts
Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts 
From Business Wire News Releases
Merck Announces US Launch of ONTRUZANT® (trastuzumab-dttb), a Biosimilar of Herceptin® (trastuzumab)
Merck Announces US Launch of ONTRUZANT® (trastuzumab-dttb), a Biosimilar of Herceptin® (trastuzumab) 
From Business Wire News Releases
KOSELUGO® (selumetinib) Approved by FDA for Pediatric Patients Two Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas
KOSELUGO Approved by FDA for Pediatric Patients 2 Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas 
From Business Wire News Releases
Merck Announces $3M Commitment to Address Critical Maternal Health Needs During COVID-19 Pandemic
Merck Announces $3M Commitment to Address Critical Maternal Health Needs During COVID-19 Pandemic 
From Business Wire News Releases
Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type
Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type 
From Business Wire News Releases
Merck Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dM
Merck Announces KEYTRUDA Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced MSI-H or dMMR Colorectal Cancer 
From Business Wire News Releases
Merck to Hold First-Quarter 2020 Sales and Earnings Conference Call on April 28
Merck to Hold First-Quarter 2020 Sales and Earnings Conference Call on April 28 
From Business Wire News Releases
Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Medical Professionals Across Merck, Pfizer and Eli Lilly Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 
From Business Wire News Releases
Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Merck & Co., Inc., (NYSE: MRK), Pfizer Inc. (NYSE: PFE), and Eli Lilly and Company (NYSE: LLY) today announced medical service volunteer programs to enable employees who are licensed medical... 
From Business Wire News Releases
Thinking about trading options or stock in Apple, Citrix Systems, Facebook, Merck, or Wayfair?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, CTXS, FB, MRK, and W. 
From PR Newswire
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with A
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death 
From Business Wire News Releases
Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response
Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response 
From Business Wire News Releases
Merck Donates a Half a Million Masks to Support COVID-19 Emergency Response in New York City
Merck Donates a Half a Million Masks to Support COVID-19 Emergency Response in New York City 
From Business Wire News Releases
Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer 
From Business Wire News Releases
Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough
Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough 
From Business Wire News Releases
Thinking about trading options or stock in Apple, Intel, Kimberly Clark, Merck, or Tesla?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, INTC, KMB, MRK, and TSLA. 
From PR Newswire
Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer 
From Business Wire News Releases
Redefining Cancer Treatment Shines Light on Cancer Immunotherapies
From PR Newswire
Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents that Block Multiple Stages of the Lifecycle of the Parasite
Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents 
From Business Wire News Releases
Merck Announces New Data from Broad HIV Program at CROI 2020
Merck Announces New Data from Broad HIV Program at CROI 2020 
From Business Wire News Releases
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
KEYTRUDA® Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Classical Hodgkin Lymphoma (cHL) 
From Business Wire News Releases
Merck to Present at the Cowen Health Care Conference
Merck to Present at the Cowen Health Care Conference 
From Business Wire News Releases
Study Shows Surprisingly Low Number of Patients Seek Trials to Treat Cancer
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Study Shows Surprisingly Low Number of Patients Seek Trials to Treat Cancer
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule
Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications (sBLAs) for KEYTRUDA Six-Week Dosing Schedule 
From Business Wire News Releases
ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification
ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification 
From Business Wire News Releases
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC)
Merck’s KEYTRUDA in Combination with Chemotherapy Met Primary Endpoint of PFS as First-Line Treatment for Metastatic Triple-Negative Breast Cancer 
From Business Wire News Releases
BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health for Phase I/IIa Combination Study of Bria-IMT™
From GlobeNewswire News Releases
Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2019. 
From Business Wire News Releases
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
80 81 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account